Immunoblotting analysis using two different commercial PRMT1 antibodies demonstrated that the upregulated protein level of PRMT1 caused by FBXO7 KD was not observed in MG132- or bortezomib-treated HCC cells (Fig. 2a, Supplementary Fig. 3g, h). This evidence concerns the gene FBXO7 and hepatocellular carcinoma.